Profile data is unavailable for this security.
About the company
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
- Revenue in USD (TTM)740.64m
- Net income in USD-289.13m
- Incorporated2000
- Employees528.00
- LocationMadrigal Pharmaceuticals Inc200 Barr Harbor Drive, Suite 400WEST CONSHOHOCKEN 19428United StatesUSA
- Phone+1 (404) 380-9263
- Fax+1 (302) 655-5049
- Websitehttps://www.madrigalpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICON PLC | 8.10bn | 599.48m | 7.10bn | 39.80k | 12.57 | 0.7608 | 7.19 | 0.8764 | 7.40 | 7.40 | 101.04 | 122.25 | 0.4806 | -- | 3.00 | 193,379.50 | 3.56 | 3.70 | 4.33 | 4.46 | 28.15 | 29.00 | 7.40 | 7.41 | -- | 5.94 | 0.2675 | -- | 1.99 | 24.17 | 29.26 | 16.18 | 27.11 | -- |
| Vaxcyte Inc | 0.00 | -657.20m | 7.63bn | 414.00 | -- | 2.43 | -- | -- | -4.84 | -4.84 | 0.00 | 22.25 | 0.00 | -- | -- | 0.00 | -19.53 | -26.00 | -20.51 | -27.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.33 | -- | 151.05 | -- |
| Nuvalent Inc | 0.00 | -381.44m | 7.79bn | 218.00 | -- | 8.62 | -- | -- | -5.32 | -5.32 | 0.00 | 11.70 | 0.00 | -- | -- | 0.00 | -35.18 | -25.32 | -37.61 | -26.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -106.59 | -- | -- | -- |
| Charles River Lbrtrs ntrntl Inc | 4.02bn | -83.48m | 7.94bn | 18.60k | -- | 2.33 | 22.85 | 1.97 | -1.56 | -1.56 | 80.18 | 69.20 | 0.5186 | 8.23 | 5.41 | 216,328.20 | -1.03 | 5.12 | -1.20 | 6.01 | 34.68 | 36.56 | -1.98 | 9.47 | 1.10 | 3.18 | 0.388 | 0.00 | -1.92 | 9.09 | -97.83 | -47.25 | 10.64 | -- |
| Cytokinetics, Inc. | 87.21m | -751.94m | 8.10bn | 498.00 | -- | -- | -- | 92.89 | -6.31 | -6.31 | 0.7328 | -4.27 | 0.0607 | -- | 85.00 | 175,122.50 | -52.35 | -45.50 | -57.39 | -50.38 | -- | -- | -862.21 | -748.37 | -- | -14.45 | 1.96 | -- | 145.34 | -7.22 | -12.03 | -- | 8.32 | -- |
| Praxis Precision Medicines Inc | 7.46m | -273.04m | 8.69bn | 116.00 | -- | 19.55 | -- | 1,165.07 | -12.90 | -12.90 | 0.3533 | 16.23 | 0.0184 | -- | -- | 64,336.21 | -67.20 | -70.37 | -75.12 | -79.85 | -- | -- | -3,658.53 | -6,809.15 | -- | -- | 0.00 | -- | 249.53 | -- | -48.30 | -- | -- | -- |
| Arrowhead Pharmaceuticals Inc | 1.09bn | 202.27m | 8.94bn | 711.00 | 41.42 | 15.43 | 34.55 | 8.19 | 1.54 | 1.54 | 7.90 | 4.14 | 0.8335 | -- | 9.86 | 1,534,432.00 | 17.84 | -25.96 | 21.44 | -30.82 | -- | -- | 21.41 | -76.01 | -- | 5.91 | 0.5068 | -- | 23,258.15 | 56.63 | 99.73 | -- | 13.66 | -- |
| Tempus AI Inc | 1.11bn | -203.88m | 9.24bn | 2.40k | -- | 18.19 | -- | 8.36 | -1.18 | -1.18 | 6.45 | 2.86 | 0.6795 | 9.29 | 5.15 | 460,524.20 | -12.53 | -53.69 | -15.38 | -72.10 | 61.73 | 45.68 | -18.45 | -84.29 | 3.12 | -3.83 | 0.7104 | -- | 30.38 | 62.05 | -180.61 | -- | 5.36 | -- |
| BIO-TECHNE Corp | 1.22bn | 79.96m | 9.38bn | 3.10k | 118.08 | 4.65 | 51.03 | 7.71 | 0.5076 | 0.5076 | 7.74 | 12.90 | 0.4682 | 2.06 | 6.04 | 392,121.60 | 3.08 | 7.62 | 3.27 | 8.13 | 66.60 | 67.49 | 6.58 | 16.74 | 3.08 | 56.92 | 0.1145 | 26.72 | 5.23 | 10.55 | -56.35 | -20.37 | -9.74 | -4.36 |
| Madrigal Pharmaceuticals Inc | 740.64m | -289.13m | 10.55bn | 528.00 | -- | 16.86 | -- | 14.25 | -13.01 | -13.01 | 33.39 | 27.56 | 0.6082 | 0.9008 | 10.30 | 1,402,727.00 | -23.74 | -68.48 | -30.98 | -85.32 | 95.25 | -- | -39.04 | -876.55 | 3.26 | -- | 0.3519 | -- | -- | -- | -24.69 | -- | 106.52 | -- |
| Summit Therapeutics Inc | 0.00 | -921.62m | 11.14bn | 159.00 | -- | 57.93 | -- | -- | -1.24 | -1.24 | 0.00 | 0.2583 | 0.00 | -- | -- | 0.00 | -241.08 | -78.31 | -287.72 | -86.84 | -- | -- | -- | -31,307.77 | -- | -- | 0.00 | -- | -- | -- | 64.01 | -- | -16.43 | -- |
| Exelixis Inc | 2.32bn | 782.57m | 11.41bn | 1.08k | 15.78 | 5.33 | 14.05 | 4.92 | 2.78 | 2.78 | 8.23 | 8.23 | 0.8011 | 3.80 | 8.40 | 2,154,249.00 | 27.02 | 13.68 | 31.41 | 15.65 | 96.39 | 96.33 | 33.73 | 20.55 | 3.50 | -- | 0.00 | 0.00 | 6.98 | 18.63 | 50.13 | 47.58 | -22.60 | -- |
| Medpace Holdings Inc | 2.53bn | 451.12m | 12.15bn | 5.90k | 27.99 | 26.39 | 25.35 | 4.80 | 15.29 | 15.29 | 85.67 | 16.22 | 1.24 | -- | 7.24 | 428,853.20 | 22.13 | 18.52 | 55.42 | 37.53 | 30.06 | 29.60 | 17.83 | 17.15 | -- | -- | 0.00 | 0.00 | 19.97 | 22.27 | 11.57 | 25.50 | 0.0102 | -- |
| Ionis Pharmaceuticals Inc | 966.96m | -256.34m | 13.06bn | 1.07k | -- | 21.02 | -- | 13.50 | -1.71 | -1.71 | 5.87 | 3.84 | 0.3163 | 0.6054 | 45.47 | 904,542.60 | -8.39 | -11.71 | -10.45 | -13.72 | 98.78 | 98.42 | -26.51 | -44.15 | 2.78 | -- | 0.7414 | -- | -10.48 | -8.88 | -23.92 | -- | 7.94 | -- |
Data as of Feb 13 2026. Currency figures normalised to Madrigal Pharmaceuticals Inc's reporting currency: US Dollar USD
62.48%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 30 Sep 2025 | 2.14m | 9.43% |
| RTW Investments LPas of 30 Sep 2025 | 1.99m | 8.78% |
| Paulson & Co., Inc.as of 30 Sep 2025 | 1.91m | 8.40% |
| Avoro Capital Advisor LLCas of 30 Sep 2025 | 1.83m | 8.07% |
| Janus Henderson Investors US LLCas of 30 Sep 2025 | 1.83m | 8.06% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.66m | 7.29% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 1.40m | 6.17% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 583.00k | 2.57% |
| Geode Capital Management LLCas of 31 Dec 2025 | 451.74k | 1.99% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 390.01k | 1.72% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
